EGFR and non-small cell lung carcinoma: However, due to the different molecular configuration and permeability of these drugs to blood-brain barrier, their activity in the treatment of patients with brain metastasis of non-small cell lung cancer is limited.23 Oxitinib is the third generation of EGFR tyrosine kinase inhibitor, which can selectively inhibit L858R / T790M EGFR mutation.